Activation of human pregnane X receptor (hPXR) has been associated with induction of chemoresistance. It has been proposed that such chemoresistance via cytochrome P450/drug transporters can be reversed with the use of antagonists that specifically abrogate agonist-mediated hPXR activation. Unfortunately, proposed antagonists lack the specificity and appropriate pharmacological characteristics that allow these features to be active in the clinic. We propose that, ideally, an hPXR antagonist would be a cancer drug itself that is part of a "cancer drug cocktail" and effective as an hPXR antagonist at therapeutic concentrations. Belinostat (BEL), a histone deacetylase inhibitor approved for the treatment of relapsed/refractory peripheral T-cell lymphoma, and often used in combination with chemotherapy, is an attractive candidate based on its hPXR ligand-like features. We sought to determine whether these features of BEL might allow it to behave as an antagonist in combination chemotherapy regimens that include hPXR activators. BEL represses agonist-activated hPXR target gene expression at its therapeutic concentrations in human primary hepatocytes and LS174T human colon cancer cells. BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities. BEL decreased rifampicin-induced resistance to SN-38, the active metabolite of irinotecan, in LS174T cells. This finding indicates that BEL could suppress hPXR agonist-induced chemoresistance. BEL attenuated the agonist-induced steroid receptor coactivator-1 interaction with hPXR, and, together with molecular docking studies, the study suggests that BEL directly interacts with multiple sites on hPXR. Taken together, our results suggest that BEL, at its clinically relevant therapeutic concentration, can antagonize hPXR agonist-induced gene expression and chemoresistance.

Department of Anatomy Physiology and Pharmacology

Zobrazit více v PubMed

Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N. (2016) A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol 78:1059–1071. PubMed

Banerjee M, Robbins D, Chen T. (2013) Modulation of xenobiotic receptors by steroids. Molecules 18:7389–7406. PubMed PMC

Borrelli F, Izzo AA. (2009) Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J 11:710–727. PubMed PMC

Calvo E, Reddy G, Boni V, García-Cañamaque L, Song T, Tjornelund J, Choi MR, Allen LF. (2016) Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies. Invest New Drugs 34:193–201. PubMed

Chai SC, Cherian MT, Wang YM, Chen T. (2016) Small-molecule modulators of PXR and CAR. Biochim Biophys Acta 1859:1141–1154. PubMed PMC

Chandran A, Vishveshwara S. (2016) Exploration of the conformational landscape in pregnane X receptor reveals a new binding pocket. Protein Sci 25:1989–2005. PubMed PMC

Chang TK, Waxman DJ. (2006) Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 38:51–73. PubMed

Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. (2012) Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 83:1112–1126. PubMed PMC

Choo EF, Woolsey S, DeMent K, Ly J, Messick K, Qin A, Takahashi R. (2015) Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. Drug Metab Dispos 43:864–869. PubMed

Cui X, Thomas A, Gerlach V, White RE, Morrison RA, Cheng KC. (2008) Application and interpretation of hPXR screening data: validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers. Biochem Pharmacol 76:680–689. PubMed

Dvorak Z, Pavek P. (2010) Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev 42:621–635. PubMed

El-Sankary W, Plant NJ, Gibson GG, Moore DJ. (2000) Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos 28:493–496. PubMed

Food and Drug Administration (2014) Beleodaq (belinostat) for injection, in Approved Drug Products with Therapeutic Equivalence Evaluations. Food and Drug Administration, White Oak, MD.

Hu ZP, Yang XX, Chen X, Cao J, Chan E, Duan W, Huang M, Yu XQ, Wen JY, Zhou SF. (2007) A mechanistic study on altered pharmacokinetics of irinotecan by St. John’s wort. Curr Drug Metab 8:157–171. PubMed

Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV, Mani S. (2007) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268. PubMed

Jones G, Willett P, Glen RC, Leach AR, Taylor R. (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727–748. PubMed

Laribi K, Alani M, Truong C, Baugier de Materre A. (2018) Recent advances in the treatment of peripheral T-cell lymphoma. Oncologist 23:1039–1053. PubMed PMC

Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, Sinha R, Penson RT, Buhl-Jensen P, Crowley E, Tjornelund J, et al. (2010) A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 103:12–17. PubMed PMC

Lee CM, Kumar V, Riley RI, Morgan ET. (2010) Metabolism and action of proteasome inhibitors in primary human hepatocytes. Drug Metab Dispos 38:2166–2172. PubMed PMC

Lee HZ, Kwitkowski VE, Del Valle PL, Ricci MS, Saber H, Habtemariam BA, Bullock J, Bloomquist E, Li Shen Y, Chen XH, et al. (2015) FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res 21:2666–2670. PubMed

Lin KT, Wang LH. (2016) New dimension of glucocorticoids in cancer treatment. Steroids 111:84–88. PubMed

Lin W, Wang YM, Chai SC, Lv L, Zheng J, Wu J, Zhang Q, Wang YD, Griffin PR, Chen T. (2017) SPA70 is a potent antagonist of human pregnane X receptor. Nat Commun 8:741. PubMed PMC

Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, et al. (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795–804. PubMed

MacLeod AK, McLaughlin LA, Henderson CJ, Wolf CR. (2015) Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models. Cancer Res 75:4573–4581. PubMed PMC

Mani S, Dou W, Redinbo MR. (2013) PXR antagonists and implication in drug metabolism. Drug Metab Rev 45:60–72. PubMed PMC

Marquard L, Petersen KD, Persson M, Hoff KD, Jensen PB, Sehested M. (2008) Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS 116:382–392. PubMed PMC

Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, Hiramatsu Y. (2005) The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol 19:1170–1180. PubMed

Nguyen L, Holland J, Miles D, Engel C, Benrimoh N, O’Reilly T, Lacy S. (2015) Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol 55:1012–1023. PubMed

Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. (2000) Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58:361–372. PubMed

Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346–6358. PubMed

Piper WL, Waddell JA, Solimando DA., Jr (2014) Drug monographs: belinostat and idelalisib. Hosp Pharm 49:1009–1013. PubMed PMC

Planque C, Rajabi F, Grillet F, Finetti P, Bertucci F, Gironella M, Lozano JJ, Beucher B, Giraud J, Garambois V, et al. (2016) Pregnane X-receptor promotes stem cell-mediated colon cancer relapse. Oncotarget 7:56558–56573. PubMed PMC

Pondugula SR, Ferniany G, Ashraf F, Abbott KL, Smith BF, Coleman ES, Mansour M, Bird RC, Smith AN, Karthikeyan C, et al. (2015a) Stearidonic acid, a plant-based dietary fatty acid, enhances the chemosensitivity of canine lymphoid tumor cells. Biochem Biophys Res Commun 460:1002–1007. PubMed

Pondugula SR, Flannery PC, Abbott KL, Coleman ES, Mani S, Samuel T, Xie W. (2015b) Diindolylmethane, a naturally occurring compound, induces CYP3A4 and MDR1 gene expression by activating human PXR. Toxicol Lett 232:580–589. PubMed PMC

Pondugula SR, Flannery PC, Apte U, Babu JR, Geetha T, Rege SD, Chen T, Abbott KL. (2015c) Mg2+/Mn2+-dependent phosphatase 1A is involved in regulating pregnane X receptor-mediated cytochrome p450 3A4 gene expression. Drug Metab Dispos 43:385–391. PubMed PMC

Pondugula SR, Mani S. (2013) Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett 328:1–9. PubMed PMC

Pondugula SR, Pavek P, Mani S. (2016) Pregnane X receptor and cancer: context-specificity is key. Nucl Receptor Res 3:101198. PubMed PMC

Poole RM. (2014) Belinostat: first global approval. Drugs 74:1543–1554. PubMed

Poulton EJ, Levy L, Lampe JW, Shen DD, Tracy J, Shuhart MC, Thummel KE, Eaton DL. (2013) Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. Toxicol Appl Pharmacol 266:122–131. PubMed PMC

Robbins D, Chen T. (2014) Tissue-specific regulation of pregnane X receptor in cancer development and therapy. Cell Biosci 4:17. PubMed PMC

Schuetz E, Lan L, Yasuda K, Kim R, Kocarek TA, Schuetz J, Strom S. (2002) Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol 62:439–445. PubMed

Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, et al. (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14:804–810. PubMed

Synold TW, Dussault I, Forman BM. (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584–590. PubMed

Takeshita A, Igarashi-Migitaka J, Nishiyama K, Takahashi H, Takeuchi Y, Koibuchi N. (2011) Acetyl tributyl citrate, the most widely used phthalate substitute plasticizer, induces cytochrome p450 3a through steroid and xenobiotic receptor. Toxicol Sci 123:460–470. PubMed

Tirona RG, Leake BF, Podust LM, Kim RB. (2004) Identification of amino acids in rat pregnane X receptor that determine species-specific activation. Mol Pharmacol 65:36–44. PubMed

Tonddast-Navaei S, Srinivasan B, Skolnick J. (2017) On the importance of composite protein multiple ligand interactions in protein pockets. J Comput Chem 38:1252–1259. PubMed PMC

Veith H, Southall N, Huang R, James T, Fayne D, Artemenko N, Shen M, Inglese J, Austin CP, Lloyd DG, et al. (2009) Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat Biotechnol 27:1050–1055. PubMed PMC

Wang H, Faucette SR, Gilbert D, Jolley SL, Sueyoshi T, Negishi M, LeCluyse EL. (2003) Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 31:620–630. PubMed

Xiao L, Nickbarg E, Wang W, Thomas A, Ziebell M, Prosise WW, Lesburg CA, Taremi SS, Gerlach VL, Le HV, et al. (2011) Evaluation of in vitro PXR-based assays and in silico modeling approaches for understanding the binding of a structurally diverse set of drugs to PXR. Biochem Pharmacol 81:669–679. PubMed

Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, et al. (2012) Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 30:3361–3367. PubMed PMC

Zhou C, Poulton EJ, Grün F, Bammler TK, Blumberg B, Thummel KE, Eaton DL. (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220–229. PubMed

Zuo R, Li F, Parikh S, Cao L, Cooper KL, Hong Y, Liu J, Faris RA, Li D, Wang H. (2017) Evaluation of a novel renewable hepatic cell model for prediction of clinical CYP3A4 induction using a correlation-based relative induction score approach. Drug Metab Dispos 45:198–207. PubMed PMC

Allosteric Antagonism of the Pregnane X Receptor (PXR): Current-State-of-the-Art and Prediction of Novel Allosteric Sites